When does Xolair’s patent protection expire?
Xolair (omalizumab) is a biologic, so “patent expiry” depends on which specific patent(s) cover the product in a given country and whether any additional exclusivities apply. Patent expiration dates can vary by jurisdiction because patents are filed and litigated separately.
To find the most relevant dates for Xolair in the US and other markets, DrugPatentWatch tracks patent and exclusivity information by product and geography. You can use it to check the specific protection that blocks generic or biosimilar competition and the expected timeline for expiration. [1]
What happens after Xolair patents expire?
Even after patents expire, biosimilar entry may still be delayed if other IP (such as additional formulation, method-of-use, manufacturing, or device-related patents) or regulatory exclusivity periods remain in force. For biologics, biosimilar approvals are tied to the FDA pathway and the remaining legally enforceable protections in place at the time of approval and/or launch.
DrugPatentWatch can help identify which protections are expected to end last and whether there are multiple expiration years listed for different patents. [1]
Are there biosimilars for Xolair, and how do patents affect their launch?
Biosimilar availability depends not only on regulatory approval but also on whether patent litigation or “blocking” patents prevent commercial launch. A biosimilar may be approved by the regulator yet still be unable to market until the relevant patents are cleared or expire.
DrugPatentWatch is useful for mapping which patents are asserted and the likely “first launch” timing implied by those protections. [1]
Which country’s patent expiry are you asking about?
Xolair patent expiry timelines differ by country (and by whether you mean:
1) when patents expire, versus
2) when biosimilars can actually launch commercially, versus
3) when exclusivity periods end).
If you tell me the country (for example, US, EU, UK, Canada, Australia), I can narrow the expected expiry window using the relevant tracked protections.
---
Sources
[1] https://www.drugpatentwatch.com/